{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:39:42Z","timestamp":1793299182724,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc"},{"DOI":"10.13039\/100004319","name":"Pfizer Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims\/hypothesis<\/jats:title>\n                    <jats:p>In previous work, we reported the HR for the risk (95% CI) of the secondary kidney composite endpoint (time to first event of doubling of serum creatinine from baseline, renal dialysis\/transplant or renal death) with ertugliflozin compared with placebo as 0.81 (0.63, 1.04). The effect of ertugliflozin on exploratory kidney-related outcomes was evaluated using data from the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes (VERTIS CV) trial (NCT01986881).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Individuals with type 2 diabetes mellitus and established atherosclerotic CVD were randomised to receive ertugliflozin 5\u00a0mg or 15\u00a0mg (observations from both doses were pooled), or matching placebo, added on to existing treatment. The kidney composite outcome in VERTIS CV (reported previously) was time to first event of doubling of serum creatinine from baseline, renal dialysis\/transplant or renal death. The pre-specified exploratory composite outcome replaced doubling of serum creatinine with sustained 40% decrease from baseline in eGFR. In addition, the impact of ertugliflozin on urinary albumin\/creatinine ratio (UACR) and eGFR over time was assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 8246 individuals were randomised and followed for a mean of 3.5\u00a0years. The exploratory kidney composite outcome of sustained 40% reduction from baseline in eGFR, chronic kidney dialysis\/transplant or renal death occurred at a lower event rate (events per 1000 person-years) in the ertugliflozin group than with the placebo group (6.0 vs 9.0); the HR (95% CI) was 0.66 (0.50, 0.88). At 60\u00a0months, in the ertugliflozin group, placebo-corrected changes from baseline (95% CIs) in UACR and eGFR were \u221216.2% (\u221223.9, \u22127.6) and 2.6\u00a0ml\u00a0min\n                      <jats:sup>\u22121<\/jats:sup>\n                      [1.73\u00a0m]\n                      <jats:sup>\u22122<\/jats:sup>\n                      (1.5, 3.6), respectively. Ertugliflozin was associated with a consistent decrease in UACR and attenuation of eGFR decline across subgroups, with a suggested larger effect observed in the macroalbuminuria and Kidney Disease: Improving Global Outcomes in Chronic Kidney Disease (KDIGO CKD) high\/very high-risk subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/interpretation<\/jats:title>\n                    <jats:p>Among individuals with type 2 diabetes and atherosclerotic CVD, ertugliflozin reduced the risk for the pre-specified exploratory composite renal endpoint and was associated with preservation of eGFR and reduced UACR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      NCT01986881\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00125-021-05407-5","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T14:02:52Z","timestamp":1614866572000},"page":"1256-1267","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":160,"title":["Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial"],"prefix":"10.1007","volume":"64","author":[{"name":"on behalf of the VERTIS CV Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4164-0429","authenticated-orcid":false,"given":"David Z. I.","family":"Cherney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Charbonnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Cosentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Dagogo-Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Pratley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weichung J.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Frederich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annpey","family":"Pong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"issue":"5","key":"5407_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1177\/1479164119842513","volume":"16","author":"J Liu","year":"2019","unstructured":"Liu J, Tarasenko L, Terra SG et al (2019) Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies. Diab Vasc Dis Res 16(5):415\u2013423. https:\/\/doi.org\/10.1177\/1479164119842513","journal-title":"Diab Vasc Dis Res"},{"issue":"17","key":"5407_CR2","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","volume":"136","author":"Y Lytvyn","year":"2017","unstructured":"Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZI (2017) Sodium glucose cotransporter-2 inhibition in heart failure: Potential mechanisms, clinical applications, and summary of clinical trials. Circulation 136(17):1643\u20131658. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030012","journal-title":"Circulation"},{"issue":"1","key":"5407_CR3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13300-017-0337-5","volume":"9","author":"G Grunberger","year":"2018","unstructured":"Grunberger G, Camp S, Johnson J et al (2018) Ertugliflozin in patients with stage 3 chronic kidney disease and type 2 diabetes mellitus: The VERTIS RENAL randomized study. Diabetes Ther 9(1):49\u201366. https:\/\/doi.org\/10.1007\/s13300-017-0337-5","journal-title":"Diabetes Ther"},{"issue":"11","key":"5407_CR4","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/jcph.955","volume":"57","author":"V Sahasrabudhe","year":"2017","unstructured":"Sahasrabudhe V, Terra SG, Hickman A et al (2017) The effect of renal impairment on the pharmacokinetics and pharmacodynamics of ertugliflozin in subjects with type 2 diabetes mellitus. J Clin Pharmacol 57(11):1432\u20131443. https:\/\/doi.org\/10.1002\/jcph.955","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"5407_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.kint.2017.06.017","volume":"93","author":"DZI Cherney","year":"2017","unstructured":"Cherney DZI, Cooper ME, Tikkanen I et al (2017) Pooled analysis of phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin. Kidney Int 93(1):231\u2013244","journal-title":"Kidney Int"},{"issue":"8","key":"5407_CR6","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/S2213-8587(17)30182-1","volume":"5","author":"DZI Cherney","year":"2017","unstructured":"Cherney DZI, Zinman B, Inzucchi SE et al (2017) Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: An exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol 5(8):610\u2013621. https:\/\/doi.org\/10.1016\/S2213-8587(17)30182-1","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"5407_CR7","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377(7):644\u2013657. https:\/\/doi.org\/10.1056\/NEJMoa1611925","journal-title":"N Engl J Med"},{"issue":"4","key":"5407_CR8","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","volume":"375","author":"C Wanner","year":"2016","unstructured":"Wanner C, Inzucchi SE, Lachin JM et al (2016) Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375(4):323\u2013334. https:\/\/doi.org\/10.1056\/NEJMoa1515920","journal-title":"N Engl J Med"},{"issue":"4","key":"5407_CR9","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380(4):347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"issue":"24","key":"5407_CR10","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B et al (2019) Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 380(24):2295\u20132306. https:\/\/doi.org\/10.1056\/NEJMoa1811744","journal-title":"N Engl J Med"},{"key":"5407_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ahj.2018.08.016","volume":"206","author":"CP Cannon","year":"2018","unstructured":"Cannon CP, McGuire DK, Pratley R et al (2018) Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). Am Heart J 206:11\u201323. https:\/\/doi.org\/10.1016\/j.ahj.2018.08.016","journal-title":"Am Heart J"},{"key":"5407_CR12","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S et al (2020) Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med 383:1425\u20131435. https:\/\/doi.org\/10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"issue":"4","key":"5407_CR13","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145(4):247\u2013254. https:\/\/doi.org\/10.7326\/0003-4819-145-4-200608150-00004","journal-title":"Ann Intern Med"},{"issue":"1","key":"5407_CR14","first-page":"19","volume":"3","author":"Work Group of Kidney Disease: Improving Global Outcomes (KDIGO)","year":"2013","unstructured":"Work Group of Kidney Disease: Improving Global Outcomes (KDIGO) (2013) Chapter 1: Definition and classification of CKD. Kidney International Supplements 2013 3(1):19\u201362","journal-title":"Kidney International Supplements 2013"},{"issue":"6","key":"5407_CR15","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","volume":"64","author":"AS Levey","year":"2014","unstructured":"Levey AS, Inker LA, Matsushita K et al (2014) GFR decline as an end point for clinical trials in CKD: A scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 64(6):821\u2013835. https:\/\/doi.org\/10.1053\/j.ajkd.2014.07.030","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"5407_CR16","doi-asserted-by":"publisher","first-page":"S135","DOI":"10.2337\/dc20-S011","volume":"43","author":"American Diabetes Association","year":"2020","unstructured":"American Diabetes Association (2020) 11. Microvascular complications and foot care: Standards of medical care in diabetes-2020. Diabetes Care 43(Suppl 1):S135\u2013S151. https:\/\/doi.org\/10.2337\/dc20-S011","journal-title":"Diabetes Care"},{"issue":"10166","key":"5407_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","volume":"393","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393(10166):31\u201339. https:\/\/doi.org\/10.1016\/S0140-6736(18)32590-X","journal-title":"Lancet"},{"issue":"11","key":"5407_CR18","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, Young T, Heerspink HJL et al (2019) SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: A systematic review and meta-analysis. Lancet Diabetes Endocrinol 7(11):845\u2013854. https:\/\/doi.org\/10.1016\/S2213-8587(19)30256-6","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"5407_CR19","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1007\/s00125-016-4017-1","volume":"59","author":"P Fioretto","year":"2016","unstructured":"Fioretto P, Stefansson BV, Johnsson E, Cain VA, Sjostrom CD (2016) Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia 59(9):2036\u20132039. https:\/\/doi.org\/10.1007\/s00125-016-4017-1","journal-title":"Diabetologia"},{"issue":"9","key":"5407_CR20","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1007\/s00125-016-4008-2","volume":"59","author":"D Cherney","year":"2016","unstructured":"Cherney D, Lund SS, Perkins BA et al (2016) The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia 59(9):1860\u20131870. https:\/\/doi.org\/10.1007\/s00125-016-4008-2","journal-title":"Diabetologia"},{"issue":"5","key":"5407_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1161\/CIRCULATIONAHA.113.005081","volume":"129","author":"DZ Cherney","year":"2014","unstructured":"Cherney DZ, Perkins BA, Soleymanlou N et al (2014) Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129(5):587\u2013597. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.113.005081","journal-title":"Circulation"},{"issue":"1","key":"5407_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","volume":"97","author":"EJM van Bommel","year":"2020","unstructured":"van Bommel EJM, Muskiet MHA, van Baar MJB et al (2020) The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int 97(1):202\u2013212. https:\/\/doi.org\/10.1016\/j.kint.2019.09.013","journal-title":"Kidney Int"},{"issue":"4","key":"5407_CR23","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1161\/CIRCULATIONAHA.118.037418","volume":"140","author":"K Kidokoro","year":"2019","unstructured":"Kidokoro K, Cherney DZI, Bozovic A et al (2019) Evaluation of glomerular hemodynamic function by empagliflozin in diabetic mice using in vivo imaging. Circulation 140(4):303\u2013315. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037418","journal-title":"Circulation"},{"issue":"2","key":"5407_CR24","doi-asserted-by":"publisher","first-page":"F184","DOI":"10.1152\/ajprenal.00043.2017","volume":"313","author":"H Rajasekeran","year":"2017","unstructured":"Rajasekeran H, Lytvyn Y, Bozovic A et al (2017) Urinary adenosine excretion in type 1 diabetes. Am J Physiol Renal Physiol 313(2):F184\u2013F191. https:\/\/doi.org\/10.1152\/ajprenal.00043.2017","journal-title":"Am J Physiol Renal Physiol"},{"issue":"12","key":"5407_CR25","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1007\/s00125-014-3396-4","volume":"57","author":"M Skrtic","year":"2014","unstructured":"Skrtic M, Yang GK, Perkins BA et al (2014) Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia 57(12):2599\u20132602. https:\/\/doi.org\/10.1007\/s00125-014-3396-4","journal-title":"Diabetologia"},{"issue":"2","key":"5407_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","volume":"60","author":"V Vallon","year":"2017","unstructured":"Vallon V, Thomson SC (2017) Targeting renal glucose reabsorption to treat hyperglycaemia: The pleiotropic effects of SGLT2 inhibition. Diabetologia 60(2):215\u2013225. https:\/\/doi.org\/10.1007\/s00125-016-4157-3","journal-title":"Diabetologia"},{"issue":"8","key":"5407_CR27","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.2337\/dc18-0394","volume":"41","author":"P Bjornstad","year":"2018","unstructured":"Bjornstad P, Laffel L, Tamborlane WV et al (2018) Acute effect of empagliflozin on fractional excretion of sodium and eGFR in youth with type 2 diabetes. Diabetes Care 41(8):e129\u2013e130. https:\/\/doi.org\/10.2337\/dc18-0394","journal-title":"Diabetes Care"},{"issue":"5","key":"5407_CR28","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/S2213-8587(13)70208-0","volume":"2","author":"AH Barnett","year":"2014","unstructured":"Barnett AH, Mithal A, Manassie J et al (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: A randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2(5):369\u2013384. https:\/\/doi.org\/10.1016\/S2213-8587(13)70208-0","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"14","key":"5407_CR29","doi-asserted-by":"publisher","first-page":"E351","DOI":"10.1503\/cmaj.191283","volume":"192","author":"C Iskander","year":"2020","unstructured":"Iskander C, Cherney DZI, Clemens KK et al (2020) Use of sodium\u2013glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: A population-based cohort study. Can Med Assoc J 192(14):E351\u2013E360. https:\/\/doi.org\/10.1503\/cmaj.191283","journal-title":"Can Med Assoc J"},{"issue":"3","key":"5407_CR30","doi-asserted-by":"publisher","first-page":"c195","DOI":"10.1159\/000327614","volume":"119","author":"HJ Lambers Heerspink","year":"2011","unstructured":"Lambers Heerspink HJ, Perkovic V, de Zeeuw D (2011) Is doubling of serum creatinine a valid clinical 'hard' endpoint in clinical nephrology trials? Nephron Clin Pract 119(3):c195\u2013c199","journal-title":"Nephron Clin Pract"},{"issue":"24","key":"5407_CR31","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.2014.6634","volume":"311","author":"J Coresh","year":"2014","unstructured":"Coresh J, Turin TC, Matsushita K et al (2014) Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA 311(24):2518\u20132531. https:\/\/doi.org\/10.1001\/jama.2014.6634","journal-title":"JAMA"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-021-05407-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-021-05407-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-021-05407-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T03:04:41Z","timestamp":1620183881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-021-05407-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":31,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["5407"],"URL":"https:\/\/doi.org\/10.1007\/s00125-021-05407-5","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"assertion":[{"value":"25 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}